![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, July 08, 2020 12:35:38 PM
It’s unbelievable anyone would tout a stock that is wildly unprofitable even with a claimed disruptive product. Especially since it’s previous incarnation did primarily the same thing. Maybe it’s the lack of transparency on the underlying patents or cloudy licensing arrangement that is floated but never appears in any disclosures. The question remains:
1. Do they own the patent on this delivery system?
2. Do they have a US exclusive licensing deal with the pharma that’s owns the patent?
I think it’s safe to say none of these points are true for GPFT. So at best they would be one of a thousand cannabis companies that is just authorized to sell it. Since they are poorly capitalized and leverage to a property that will be months if not a year to complete. Given that I don’t see how this company is worth anywhere near 12M.
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM